🇺🇸 FDA
Pipeline program

An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

TG1-CL-301

Phase 2 other active

Quick answer

An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies for Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy is a Phase 2 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy
Phase
Phase 2
Modality
other
Status
active

Clinical trials